FFCD/SFRO study (French).Arm 1: RT (60 Gy) + CI 5-FU + intermittent cisplatin → maintenance gemcitabine; arm 2: induction gemcitabine → maintenance gemcitabine. Upfront CRT was more toxic and had worse survival outcomes. MS was 8.6 mos vs. 13 mos, and 1-yr OS was 32% vs. 53%. Criticism: The upfront CRT was not standard and was very poorly tolerated. (ChauffertB et al., Ann Oncol 2008)